FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999328892> ?p ?o ?g. }

• W1999328892 endingPage "152" @default.
• W1999328892 startingPage "147" @default.
• W1999328892 abstract "Platelet activation and deposition in brain microvessels appear to be key events in the pathogenesis of ischemia-induced neuronal degeneration and behavioral deficits. It has been hypothesized that activated platelets in combination with polymorphonuclear leukocytes and fibrin may play a role in vessel reocclusion leading to the no-reflow phenomenon after administration of the thrombolytic tissue plasminogen activator (tPA). We studied the effects of the novel glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 when administered in combination with tPA on infarct and hemorrhage rate and volume to determine whether activated platelets are involved in either infarct or hemorrhage generation after a thromboembolic stroke.One hundred thirty-two male New Zealand White rabbits were included in the present study. Rabbits were embolized by injecting a blood clot into the middle cerebral artery via a catheter. Five or 65 minutes after embolization, SM-20302 (5 mg/kg) was infused intravenously. In drug combination studies, tPA was infused intravenously for 30 minutes starting 60 minutes after embolization, and SM-20302 was administered 5 or 65 minutes after embolization. Postmortem analysis included assessment of hemorrhage, infarct size and location, and clot lysis.In the vehicle control group, the hemorrhage rate after a thromboembolic stroke was 33%. There was a significant increase (109%) in the hemorrhage rate in the group of rabbits treated with the thrombolytic tPA. SM-20302 by itself did not significantly alter the embolism-induced hemorrhage rate when administered either 5 or 65 minutes after embolism. The SM-20302 groups had a 42% and 33% incidence of hemorrhage in the 5- and 65-minute groups, respectively. In groups treated with a combination of drugs, the SM-20302/tPA group had a 31% and 71% incidence of hemorrhage when SM-20302 was administered 5 and 65 minutes after embolization, respectively. SM-20302 in combination with tPA also significantly increased infarct rate, but not hemorrhage or infarct volume.This study suggests that treatment of thromboembolic stroke with the combination of a platelet inhibitor and tPA may have a beneficial outcome on the basis of the following: First, acute administration of SM-20302 did not significantly increase hemorrhage rate. Second, SM-20302 in combination with tPA significantly reduced tPA-induced intracerebral hemorrhage. Third, there appears to be a specific window of opportunity when a platelet inhibitor must be administered to produce a beneficial effect. Overall, on the basis of our results, we hypothesize that the increased rate of intracerebral hemorrhage observed after tPA administration may be partly due to increased reocclusion of cerebral vessels following lysis of the emboli and that reocclusion can be controlled by administration of a platelet inhibitor." @default.
• W1999328892 created "2016-06-24" @default.
• W1999328892 creator A5016280147 @default.
• W1999328892 creator A5028934169 @default.
• W1999328892 creator A5041381739 @default.
• W1999328892 creator A5060081589 @default.
• W1999328892 date "2002-01-01" @default.
• W1999328892 modified "2023-09-23" @default.
• W1999328892 title "The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator–Induced Intracerebral Hemorrhage After Thromboembolic Stroke" @default.
• W1999328892 cites W130319287 @default.
• W1999328892 cites W1512461647 @default.
• W1999328892 cites W1971347344 @default.
• W1999328892 cites W1976299524 @default.
• W1999328892 cites W1976425448 @default.
• W1999328892 cites W1983062928 @default.
• W1999328892 cites W1991509908 @default.
• W1999328892 cites W2008031785 @default.
• W1999328892 cites W2025464240 @default.
• W1999328892 cites W2033767918 @default.
• W1999328892 cites W2033827787 @default.
• W1999328892 cites W2069039926 @default.
• W1999328892 cites W2069157080 @default.
• W1999328892 cites W2081513903 @default.
• W1999328892 cites W2090052232 @default.
• W1999328892 cites W2121995634 @default.
• W1999328892 cites W2123199591 @default.
• W1999328892 cites W2292308933 @default.
• W1999328892 cites W2323429573 @default.
• W1999328892 cites W2326282101 @default.
• W1999328892 cites W2417166978 @default.
• W1999328892 cites W2419174135 @default.
• W1999328892 doi "https://doi.org/10.1161/hs0102.100530" @default.
• W1999328892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11779904" @default.
• W1999328892 hasPublicationYear "2002" @default.
• W1999328892 type Work @default.
• W1999328892 sameAs 1999328892 @default.
• W1999328892 citedByCount "33" @default.
• W1999328892 countsByYear W19993288922012 @default.
• W1999328892 countsByYear W19993288922013 @default.
• W1999328892 countsByYear W19993288922014 @default.
• W1999328892 countsByYear W19993288922015 @default.
• W1999328892 countsByYear W19993288922016 @default.
• W1999328892 countsByYear W19993288922019 @default.
• W1999328892 countsByYear W19993288922020 @default.
• W1999328892 crossrefType "journal-article" @default.
• W1999328892 hasAuthorship W1999328892A5016280147 @default.
• W1999328892 hasAuthorship W1999328892A5028934169 @default.
• W1999328892 hasAuthorship W1999328892A5041381739 @default.
• W1999328892 hasAuthorship W1999328892A5060081589 @default.
• W1999328892 hasConcept C126322002 @default.
• W1999328892 hasConcept C127413603 @default.
• W1999328892 hasConcept C141071460 @default.
• W1999328892 hasConcept C203014093 @default.
• W1999328892 hasConcept C2776035437 @default.
• W1999328892 hasConcept C2776572282 @default.
• W1999328892 hasConcept C2777094939 @default.
• W1999328892 hasConcept C2777736543 @default.
• W1999328892 hasConcept C2780645631 @default.
• W1999328892 hasConcept C3018697912 @default.
• W1999328892 hasConcept C42219234 @default.
• W1999328892 hasConcept C54173615 @default.
• W1999328892 hasConcept C71924100 @default.
• W1999328892 hasConcept C78519656 @default.
• W1999328892 hasConcept C89560881 @default.
• W1999328892 hasConcept C98274493 @default.
• W1999328892 hasConceptScore W1999328892C126322002 @default.
• W1999328892 hasConceptScore W1999328892C127413603 @default.
• W1999328892 hasConceptScore W1999328892C141071460 @default.
• W1999328892 hasConceptScore W1999328892C203014093 @default.
• W1999328892 hasConceptScore W1999328892C2776035437 @default.
• W1999328892 hasConceptScore W1999328892C2776572282 @default.
• W1999328892 hasConceptScore W1999328892C2777094939 @default.
• W1999328892 hasConceptScore W1999328892C2777736543 @default.
• W1999328892 hasConceptScore W1999328892C2780645631 @default.
• W1999328892 hasConceptScore W1999328892C3018697912 @default.
• W1999328892 hasConceptScore W1999328892C42219234 @default.
• W1999328892 hasConceptScore W1999328892C54173615 @default.
• W1999328892 hasConceptScore W1999328892C71924100 @default.
• W1999328892 hasConceptScore W1999328892C78519656 @default.
• W1999328892 hasConceptScore W1999328892C89560881 @default.
• W1999328892 hasConceptScore W1999328892C98274493 @default.
• W1999328892 hasIssue "1" @default.
• W1999328892 hasLocation W19993288921 @default.
• W1999328892 hasLocation W19993288922 @default.
• W1999328892 hasOpenAccess W1999328892 @default.
• W1999328892 hasPrimaryLocation W19993288921 @default.
• W1999328892 hasRelatedWork W1983567391 @default.
• W1999328892 hasRelatedWork W2088277704 @default.
• W1999328892 hasRelatedWork W2165041925 @default.
• W1999328892 hasRelatedWork W2279781996 @default.
• W1999328892 hasRelatedWork W2414630771 @default.
• W1999328892 hasRelatedWork W2463468111 @default.
• W1999328892 hasRelatedWork W2991583870 @default.
• W1999328892 hasRelatedWork W39530504 @default.
• W1999328892 hasRelatedWork W4235209101 @default.
• W1999328892 hasRelatedWork W72843305 @default.
• W1999328892 hasVolume "33" @default.
• W1999328892 isParatext "false" @default.

• next